A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
Clinical trial NCT07459751 · RECRUITING
Trial details
- NCT number
- NCT07459751
- Sponsor
- Shanghai Henlius Biotech
- Status
- RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-05-27
- Primary completion
- 2030-01-15
- Enrollment
- 706
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.